Yunlong Wang: Clinical Trials

3 trials sponsored by Yunlong Wang, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 not yet recruiting. 2 Phase 4, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 42Not yet recruiting 2
Not applicable1Not yet recruiting 1

Follow Yunlong Wang: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Tirzepatide, Structured Lifestyle Intervention - Atrial Fibrillation, Obesity & Overweight
Phase 4Not yet recruitingYunlong Wang7102026-09-012026-07-21
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
Tirzepatide, Structured Lifestyle Intervention - Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase 4Not yet recruitingYunlong Wang6022026-08-012026-06-05
The COMBINE-AF Trial
Linear ablation of mitral isthmus and tricuspid isthmus, Ethanol, Radiofrequency Ablation Catheter - Atrial Fibrillation (AF), Atrial Fibrillation Catheter Ablation
Not applicableNot yet recruitingYunlong Wang4302026-07-272026-07-27

Conditions studied

Atrial Fibrillation (3)  ·  Obesity (2)  ·  Overweight (1)

Interventions

Tirzepatide (2)  ·  Catheter Ablation (1)  ·  Ethanol (1)

Countries

China (2)